

# Hong Kong

# Overweight (no change)

## **Highlighted Companies**

# AIA Group ADD, TP HK\$91.00, HK\$63.00 close

AIA Group is our sector top pick. We see significant new business premium growth potential in China driving continued operational outperformance vs. peers and we think its 2023 underperformance offers a highly attractive entry point.

# Ping An Insurance ADD, TP HK\$80.00, HK\$32.55 close

We believe Ping An Insurance is well placed to benefit from rebounding new business value growth, on the back of its strong agent force, the benefits of its completed agent reform, and strong demand for savings insurance products.

## Prudential PLC ADD, TP HK\$114.0, HK\$80.5 close

We see numerous tailwinds for Prudential (Pru) in the medium and long term, which could drive a closing of its sizeable P/EV valuation gap vs. AIA. We think changes that could be introduced by its incoming new CEO are positive.

## **Summary Valuation Metrics**

P/E (x)	Dec-23F	Dec-24F	Dec-25F
AIA Group	28.81	12.52	11.54
Ping An Insurance	3.54	2.76	2.35
Prudential PLC	20.69	12.93	10.80
P/BV (x)	Dec-23F	Dec-24F	Dec-25F
AIA Group	2.64	2.40	2.10
Ping An Insurance	0.55	0.47	0.40
Prudential PLC	1.60	1.46	1.33
Dividend Yield	Dec-23F	Dec-24F	Dec-25F
AIA Group	2.44%	2.58%	2.80%
Ping An Insurance	8.79%	10.06%	11.90%
Prudential PLC	1.34%	1.28%	1.42%

#### Analyst(s)



#### Michael CHANG, CFA

T (852) 2539 1323

E michael.chang@cgs-cimb.com

Laura LI Zhiyi

T (852) 2532 1127

E laura.li@cgs-cimb.com

# **Insurance - Life**

# MCV: The differences post-pandemic

- We are confident that the average case sizes of MCV insurance policies in FY24F-25F can remain well above pre-pandemic norms.
- This is mainly because we see the post-pandemic shift towards brokers, savings products and shorter-duration payment products continuing.
- We believe US\$122.6bn of non-Rmb mainland China household deposits in Nov 2023 (Fig 20) represents a potential profit pool for HK insurers' MCV.
- With China's stable forex reserves, we think MCV-related policy risks appear low. Retain sector Overweight. Sector top picks: AIA and Prudential (Pru).

# Average MCV insurance policy case sizes could remain high

We are confident that the case sizes of insurance policies purchased by Mainland Chinese visitors (MCV) in HK in FY24F-25F could stay well above pre-pandemic levels. A persistent investor concern has been the sustainability of these large case sizes, with 9M23 system MCV average policy case size at 3.2x 2018's levels (Fig 3). Higher case sizes in 9M23 vs. 2018 were due to: 1) greater reliance on the broker channel to drive MCV sales, which have larger case sizes (Fig 4), 2) a higher mix of shorter-duration premium-payment products (Fig 10) plus savings insurance and whole life policies (Fig 11), and 3) a higher mix of single premiums within first-year premiums (Fig 24). We see these factors largely persisting in FY24F-25F (see *Resilience in MCV insurance demand*, dated 4 Dec 2023).

# Some signs of a turnaround in the falling agent number trend

Recent HK agent data is encouraging, in our view, with Dec 2023's 1.1% mom rise in agent numbers being the second consecutive mom increase of more than 1% (Fig 26). Nevertheless, agent numbers still slumped 11% yoy in Dec 2023, despite the rapid recovery of the MCV insurance business and announcement of more aggressive agent growth targets by major HK insurers in early-2023 (Fig 28). While Dec 2023's growth rate has improved from Jul 2023's -17% yoy lows, it is still markedly worse vs. pre-pandemic agent growth of 23% yoy in Aug 2019 (Fig 25). We believe that agent number growth is important, as the agent channel is higher-margin and less subject to price competition than the broker channel (HK Insurance: The battle for MCV heats up in HK, dated 10 Aug 2023).

#### US\$122.6bn non-Rmb deposits in China a potential profit pool

People's Bank of China (PBOC) data indicates US\$122.6bn of non-Rmb household deposits in Mainland China as of Nov 2023; we think that this represents a potential profit pool for HK insurers' MCV business (Fig 20). To put things in perspective, MCV insurance sold in HK in 9M23 only totalled US\$6bn on an unweighted basis and US\$3.9bn on a weighted basis. With Tier 1 cities closer to HK seeing a greater fall in non-Rmb deposits than those further away (Fig 1), we think this suggests that people in these regions may be going to HK to buy higher-yielding US\$ insurance policies.

# Reiterate sector Overweight; Sector top picks are AIA and Pru

Unlike pre-pandemic, we think that MCV-related policy risks are still low, with China's forex reserves remarkably stable over 2020-23 (in marked contrast to the 2014-16 period; Fig 31). Our sector OW call is premised on favourable new business premium growth trends amid inexpensive valuations. Potential re-rating catalysts: stronger-for-longer MCV insurance demand and faster agent growth. Key downside risks: stricter capital controls on HK insurance products and a global recession hurting insurance demand.

# Figure 1: A larger fall of non-Rmb deposits in Tier 1 cities closer to HK since Feb 2023 suggests that people in these cities are more likely to buy US\$ insurance policies in HK

Shenzhen Guangzhou Beijing Shanghai Fujian Chongqing Nationwide

Percentage change -18% -6% 2% 2% -4% -3% 2% 2% over Feb - Nov 2023

SOURCES: CGS-CIMB RESEARCH, PBOC



	Ticker	Rec	Market Cap	Price	Target Price	+/-	P/EV	(x)	VO multip		P/BV	(x)	Group		ROE	(%)	P/E	(x)	Divid yield	
			(US\$bn)	(Lcy)	(Lcy)	(%)	FY23F	FY24F	FY23F	FY24F	FY23F	FY24F	FY23F	FY24F	FY23F	FY24F	FY23F	FY24F	FY23F	FY24F
China Life	2628 HK	Add	98.05	9.28	17.00	83%	0.17x	0.15x	-34.3x	-34.1x	0.5x	0.4x	11.1x	10.9x	14.3x	14.3x	3.5x	3.2x	10.5	11.5
Ping An	2318 HK	Add	96.17	32.55	80.00	146%	0.36x	0.33x	-31.1x	-31.6x	0.6x	0.5x	14.1x	12.5x	17.1x	17.3x	3.3x	2.8x	8.8	9.8
CPIC	2601 HK	Add	28.74	15.10	32.10	113%	0.24x	0.22x	-40.8x	-41.2x	0.6x	0.5x	12.0x	10.3x	11.6x	11.4x	4.6x	4.3x	8.3	9.6
NCI	1336 HK	Hold	11.24	14.36	20.70	44%	0.15x	0.14x	-81.1x	-77.7x	0.4x	0.3x	8.9x	7.7x	12.0x	13.8x	3.3x	2.6x	10.4	13.1
PICC P&C	2328 HK	Add	26.37	9.74	10.20	5%	n.a.	n.a.	n.a.	n.a.	0.9x	0.8x	n.a.	n.a.	13.3x	12.5x	6.9x	6.8x	5.8	5.9
AIA	1299 HK	Add	97.97	63.00	91.00	44%	1.38x	1.28x	6.0x	3.7x	2.6x	2.4x	7.2x	12.7x	9.8x	19.9x	26.0x	12.5x	2.4	2.6
Pru	2378 HK	Add	29.49	80.50	114.00	42%	0.63x	0.56x	-5.7x	-6.0x	1.6x	1.5x	10.5x	13.9x	7.8x	11.7x	20.7x	12.9x	1.3	1.3
Manulife	945 HK	NR	35.13	168.50	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1.3x	1.2x	n.a.	n.a.	14.2x	14.6x	8.9x	8.3x	5.0	5.3
HK-listed v	veighted a	verage					0.59x	0.54x	-22.2x	-22.8x	1.2x	1.0x	10.8x	11.9x	13.5x	16.2x	9.9x	6.0x	7.3	8.1
HK-listed v	veiahted a	verage	ex AIA. Pru	and Mar	nulife		0.25x	0.23x	-36.0x	-36.0x	0.6x	0.5x	12.3x	11.3x	14.8x	14.9x	3.9x	3.5x	9.1	10.2

\*CPIC: China Pacific Insurance Company; NCI: New China Life Insurance; PICC P&C: PICC (The People's Insurance Company of China) Property & Casualty); Pru: Prudential plc SHARE PRICE DATA AS OF 8 JAN 2023

SOURCES: CGS-CIMB RESEARCH ESTIMATES, COMPANY REPORTS, BLOOMBERG Note: Estimates for Not Rated (NR) companies are based on Bloomberg consensus



# MCV: The differences post-pandemic

Figure 3: Average	Figure 3: Average MCV insurance case sizes (regular premiums				Figure 4: Average policy size in the agent and broker channels						
vs. single premi	ums) (HK\$)			for selected insurers							
(HK\$)	Regular premium policies	Single premium policies	All policies	(HK\$)	AIA	Pru	Manulife	FWD	System		
2006	50,941	723,219	131,752	3Q23							
2007	56,154	892,619	183,634	Agent channel							
2008	56,950	821,607	119,212	Regular premium	49,675	76,955	26,504	23,470	49,125		
2009	64,083	850,650	90,467	Single premium	603,113	286,871	548,964	661,727	495,846		
2010	70,832	1,175,066	96,520	Broker channel							
2011	71,343	1,876,693	96,958	Regular premium	192,659	276,463	372,281	134,987	293,962		
2012	73,727	3,133,138	118,925	Single premium	1,889,715	3,035,842	9,479,546	3,781,526	5,438,319		
2013	73,232	4,170,145	138,084	2Q23							
2014	73,153	5,049,491	152,596	Agent channel							
2015	75,415	3,875,420	128,679	Regular premium	56,133	97,717	29,834	21,950	59,215		
2016	105,836	2,803,353	177,055	Single premium	571,323	453,879	460,078	914,086	515,083		
2017	84,156	2,562,124	124,104	Broker channel							
2018	82,717	1,986,939	102,597	Regular premium	213,478	349,930	381,797	173,161	303,290		
2019	104,930	1,953,732	125,732	Single premium	1,514,046	1,586,229	10,510,905	3,200,673	6,984,450		
2020	173,751	3,632,158	232,730	1Q23							
2021	80,797	1,866,108	155,454	Agent channel							
2022	158,764	4,269,829	358,885	Regular premium	52,296	92,565	30,005	33,308	52,892		
1Q23	186,553	3,015,042	278,606	Single premium	508,011	453,821	396,786	1,132,590	476,595		
2Q23	218,353	4,547,735	397,175	Broker channel							
3Q23	212,827	2,907,414	290,504	Regular premium	189,226	261,882	307,647	56,949	213,271		
9M23	208,599	3,703,817	329,730	Single premium	1,948,778	615,955	11,932,919	3,170,879	3,926,407		
3Q23 qoq	-2.5%	-36.1%	-26.9%	FY19							
Ratio of 3Q23 to	2.6x	1.5x	2.8x	Agent channel							
2018				Regular premium	33,353	52,573	16,866	41,416	36,959		
Ratio of 9M23 to	2.5x	1.9x	3.2x	Single premium	596,248	587,942	486,752	2,681,395	557,242		
2018				Broker channel							
				Regular premium	86,765	110,579	136,130	249,622	194,834		
				Single premium	7,544,287	900,132	12,544,185	3,957,602	5,825,995		
				FY18							
				Agent channel							
				Regular premium	34,732	50,978	28,072	35,317	39,039		
				Single premium	557,691	611,973	432,716	1,756,726	503,388		
				Broker channel							
				Regular premium	75,817	100,158	40,761	218,532	121,137		
				Single premium	9,173,073	814,186	16,525,464	2,308,002	5,192,817		

Figure 5: System mix of new business premiums (annualised new premium [ANP] weighted) by distribution channel, by quarter

Figure 6: System growth yoy of new business premiums (ANP weighted) by distribution channel, by quarter

	Agent	Bancassurance	Broker	Other	Total		Agent	Bancassurance	Broker	Other	Total
1Q18	27%	54%	18%	1%	100%	1Q18	-10%	19%	-12%	25%	3%
2Q18	33%	50%	16%	1%	100%	2Q18	18%	11%	32%	31%	16%
3Q18	36%	47%	17%	1%	100%	3Q18	15%	4%	41%	-24%	13%
4Q18	46%	37%	15%	1%	100%	4Q18	22%	-5%	15%	14%	9%
1Q19	25%	57%	17%	1%	100%	1Q19	14%	34%	16%	110%	26%
2Q19	29%	45%	24%	2%	100%	2Q19	26%	31%	117%	290%	45%
3Q19	32%	46%	21%	1%	100%	3Q19	2%	11%	46%	123%	15%
4Q19	48%	38%	14%	1%	100%	4Q19	-16%	-16%	-26%	-45%	-18%
1Q20	25%	58%	16%	1%	100%	1Q20	-37%	-37%	-42%	-19%	-37%
2Q20	22%	62%	13%	4%	100%	2Q20	-62%	-32%	-73%	-20%	-50%
3Q20	26%	58%	13%	3%	100%	3Q20	-43%	-10%	-57%	99%	-29%
4Q20	41%	38%	17%	5%	100%	4Q20	-37%	-26%	-10%	355%	-26%
1Q21	21%	62%	14%	3%	100%	1Q21	-15%	6%	-11%	95%	-1%
2Q21	23%	52%	17%	8%	100%	2Q21	9%	-15%	35%	123%	2%
3Q21	25%	55%	18%	2%	100%	3Q21	-8%	-10%	28%	-38%	-5%
4Q21	40%	39%	19%	3%	100%	4Q21	8%	14%	24%	-39%	11%
1Q22	21%	54%	22%	3%	100%	1Q22	-28%	-36%	15%	-25%	-27%
2Q22	28%	49%	19%	3%	100%	2Q22	-12%	-31%	-22%	-71%	-28%
3Q22	34%	50%	14%	2%	100%	3Q22	-19%	-47%	-54%	-41%	-41%
4Q22	48%	36%	14%	2%	100%	4Q22	-30%	-48%	-58%	-58%	-43%
1Q23	31%	53%	15%	1%	100%	1Q23	124%	50%	4%	-32%	53%
2Q23	32%	36%	30%	2%	100%	2Q23	134%	47%	224%	32%	105%
3Q23	28%	43%	27%	2%	100%	3Q23	91%	98%	357%	90%	131%
			SOURCE: C	GS-CIMB RES	EARCH, IA				SOURCE: CG	S-CIMB RESE	ARCH, IA






Figure 8: Market share of the broker channel in 9M23, 1H23 and 3Q23 (by HK ANP) vs. 2018 and 2016 (%)

No. Insurer	9M23	1H23	3Q23	2018	2016
1 AIA	14.6	15.3	13.4	36.1	29.3
2 FT Life	10.8	12.3	8.2	5.5	1.4
3 BOC Life	10.6	8.6	14.3	2.6	2.4
4 Manulife	9.8	10.4	8.6	2.7	0.8
9 Sun Life	8.7	6.2	13.2	1.8	2.7
5 Axa	8.4	9.6	6.3	4.7	2.8
6 Prudential	8.0	7.9	8.1	4.2	12.2
8 China Life	7.2	7.0	7.5	9.1	28.7
7 YF Life	6.6	7.3	5.3	1.7	2.0
10 FWD	5.7	5.6	5.8	4.6	3.5
11 TP Life	2.5	3.7	0.4	13.6	3.8
Total of 11 insurers	92.8	93.8	91.0	86.6	89.6


SOURCES: CGS-CIMB RESEARCH IA



Figure 9: Growth yoy of HK system's first-year premiums by premium-payment duration

	Single	<5 years	≥5 but <10 yrs	≥10 but <25 yrs	≥25 yrs
2016	19%	79%	78%	19%	-10%
2017	-15%	-26%	-7%	-4%	7%
2018	-7%	13%	10%	1%	29%
2019	-15%	21%	29%	-10%	16%
2020	18%	-31%	-52%	-49%	-25%
2021	60%	2%	-13%	-14%	0%
2022	-6%	-41%	-37%	-24%	-28%
1Q23	-18%	31%	209%	78%	-6%
2Q23	8%	52%	445%	68%	21%
3Q23	-10%	152%	269%	49%	9%
9M23	-6%	64%	297%	63%	8%

Figure 10: Premium duration structure of the HK life insurance industry's regular premiums (new business) of its individual life business



SOURCES: CGS-CIMB RESEARCH, IA

SOURCES: CGS-CIMB RESEARCH, IA

Figure 11: Mix of life insurance products bought by MCV in HK across time										
(%)	2016	2017	2018	2019	2020	2021	2022	1Q23	2Q23	3Q23
Whole life	53.2	58.3	58.0	55.6	45.2	48.5	69.7	83.2	83.0	82.4
Endowment	18.8	9.0	4.8	11.1	37.1	15.6	6.2	4.4	4.7	5.7
Universal life	8.1	7.9	9.9	12.4	6.1	6.3	5.5	2.6	2.0	1.8
Term Life	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.1	0.1
Medical	0.2	0.3	0.3	0.3	0.4	1.9	1.3	0.2	0.2	0.2
Critical illness	11.1	14.7	16.6	12.8	7.3	15.3	9.3	4.7	4.3	4.5
Annuities	0.6	0.9	1.6	6.5	2.8	2.2	3.9	4.1	5.2	4.8
Other	6.2	7.1	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accident & sickness (medical) rider	0.6	0.6	0.6	0.4	0.3	1.4	0.8	0.2	0.2	0.2
Accident & sickness (non- medical) riders	0.3	0.3	0.2	0.1	0.0	0.2	0.1	0.0	0.0	0.0
Riders other than accident & sickness	0.1	0.1	0.1	0.1	0.3	5.1	1.8	0.0	0.0	0.0
Unit-linked	0.7	0.8	0.9	0.6	0.4	3.4	1.2	0.4	0.4	0.4
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0







Figure 13: There had been a very strong visible relationship between the US\$/Rmb exchange rate and ANP for insurance sold to mainland Chinese individuals in Dec 2012-Jun 2019 (correlation co-efficient of 91%).



SOURCES: CGS-CIMB RESEARCH, INSURANCE AUTHORITY, BLOOMBERG

nclude medical reimbursement, critical illness and health insurance riders in the medical egory. We include term life, other protection and non-medical riders in the protection category nclude universal life, endowment and annuities in the savings category. In our view, whole life

Figure 14: The gap between the US and China 10-year government bond yields has been positive since Jul 2022, after being consistently negative since Jul 2010, and is now at a record high (at least since data became available in 2005)




Figure 15: China's treasury bond yields have been trending downwards, with its 10-year treasury bond yield recently falling to a record low



SOURCES: CGS-CIMB RESEARCH, BLOOMBERG

Figure 16: There is a clear strong correlation between onshore non-Rmb household deposits and the US\$/Rmb exchange rate since the start of 2017



Figure 17: The correlation coefficient between onshore non-Rmb deposits and the US\$/Rmb exchange rate was the highest during the pandemic when the mainland China travel border was closed

> Correlation coefficient between onshore non-Rmb deposits and the US\$/ Rmb exchange rate

SOURCES: CGS-CIMB RESEARCH, WIND, PBOC, BLOOMBERG

Jan 2017 - Jan 2020	53%
Feb 2020 - Jan 2023	91%
Feb 2023 - Nov 2023	66%
Jan 2017 - Nov 2023	82%

# Figure 18: There has been a marked shift from onshore China non-Rmb deposits to placing US\$ funds in HK for MCV in the 3 years pre-pandemic, as well as in 2023-YTD

	Change in onshore non-Rmb household deposits for mainland Chinese (Rmb bn)	MCV insurance premiums during period (Rmb bn)	Change in onshore non- Rmb household deposits for mainland Chinese plus MCV insurance premiums (Rmb bn)	Percentage mix to MCV insurance	US\$/Rmb
2015	140	26	166	16%	6.49
2016	293	63	356	18%	6.95
2017	-60	44	-16	-274%	6.51
2018	24	40	64	63%	6.88
2019	-16	38	23	168%	6.96
2020	14	6	20	31%	6.53
2021	-32	1	-31	-2%	6.36
2022	56	2	58	3%	6.90
9M23	26	43	69	62%	7.30
of which:					
1Q23	19	8	27	31%	6.87
2Q23	20	21	41	51%	7.25
3Q23	-13	14	1	1568%	7.30
4Q23 QTD	-15	n.a.	n.a.	n.a.	n.a.
	The changes of		IMB RESEARCH, PBOC, WIND, IN		` ′

The changes above are yoy for annual periods, hoh for half-yearly periods, and gog for guarterly periods

Figure 19: Percentage change in non-Rmb deposits over the Feb 2023-Nov 2023 period in mainland China

period in maina	iid Oiliiid						
	Shenzhen	Guangzhou	Beijing	Shanghai	Fujian	Chongqing	Nationwide
Percentage change in non-Rmb deposits over Feb - Nov 2023	-18%	-6%	2%	2%	-4%	-3%	2%
				SOLIE	0000.000	CIMP DECEMBOI	H WIND DDOC






Figure 21: A summary of the advertised board rate cuts to Rmb deposits by China's big four banks plus BOCOM and CMB on their websites as of Jun 2023, Sep 2023 and Dec 2023; We believe that China banks also cut their US\$ deposit rates in Jul 2023

	Dec 2023 rate	Dec 2023 change	Sep 2023 change	Jun 2023 change
Demand deposits	0.20%	0bp	0bp	-5bp
3-month time deposits	1.15%	-10bp	0bp	0bp
6-month time deposits	1.35%	-10bp	0bp	0bp
1-year time deposits	1.45%	-10bp	-10bp	0bp
2-year time deposits	1.65%	-20bp	-20bp	-10bp
3-year time deposits	1.95%	-25bp	-25bp	-15bp
5-year time deposits	2.00%	-25bp	-25bp	-15bp
		SOURCES: (	CGS-CIMB RESEARCH,	COMPANY REPORTS

Figure 22: Time deposit rates for the 5-year tenor fell at a faster rate over the Apr 2022-Dec 2023 period, compared to other tenors, for China's big four banks 3.00% 2.75% 2.65% 2 50% 2.50% 2.25% 2.00% 2.00% 1.50% 1.00% 0.50% 0.00% Demand 3-month time 6-month time 1-year time deposits deposits deposits deposits deposits deposits --- Jun-2023 Sep-2023 SOURCES: CGS-CIMB RESEARCH, COMPANY REPORTS, BLOOMBERG, SINA.COM



Figure 23: The mix of ANP from MCV to the HK system in 2Q23 of 44.3% has almost recovered back to 4Q16's peak of 45.8% (quarterly data)




Figure 24: The mix of single premiums within MCV premiums had risen significantly during the pandemic and remains relatively elevated in 9M23




Figure 25: Since Apr 2022, the number of monthly HK life insurance agents has been falling yoy at a pace that has not been seen in at least 18 years



Figure 26: 28 out of the last 29 months up to end-Aug 2023 had agent numbers staying flat or falling mom







Figure 27: Insurance agent numbers in HK and yoy growth since Figure 28: HK insurance agent recruitment targets announced 2000 (both life and general insurance)



by AIA, Prudential and Manulife in early-mid 2023

	Targets
AIA	Add 5,000 financial planners to its workforce
Prudential	Add 2,000 advisers to its team
Manulife	Hire 3,000 agent before end-2023

SOURCES: CGS-CIMB RESEARCH, COMPANY REPORTS, THE STANDARD

Figure 29: HK agent ANP per average agent had fallen the most for AIA and Pru over the 2018-2022 period, which we think suggests that the agent productivity of these two insurers were most hurt by the pandemic

(HK\$)	2018	2019	2020	2021	2022	2022 vs 2018 change
AIA	822,064	766,181	346,325	326,886	300,188	-63%
Pru	689,678	554,555	175,735	114,031	108,063	-84%
Manulife	420,970	428,424	374,096	360,773	248,786	-41%
FWD	398,658	480,930	354,984	318,627	187,202	-53%
	SOURCES: CGS	G-CIMB RESEA	RCH, COMPA	NY REPORTS	, INSURANCE	AUTHORITY

Figure 30: MDRTs in Hong Kong (HK): Comparing the 2022 performance year vs. the 2018 performance year - AIA, Prui and Axa saw the biggest falls

	MDRT fall in 2022 versus 2018	2022 HK MDRT agent numbers
AIA	-39%	2,443
Prudential	-82%	743
Axa	-50%	381
Manulife	19%	1,393
FWD	-4%	388
	SOURCES: CGS-CIMB RESEARCH, MILLION DO	OLLAR ROUND TABLE (MDRT) ORGANISATION

Figure 31: China's forex reserves have been very stable since early-2017, after falling steadily over the Jun 2014-Jan 2017 period





Figure 32: The PBOC had announced 146bp of cuts in the 1-year loan benchmark rate in Oct 2014-Oct 2015, vs. only 20bp of cuts in 2023 to the 1-year loan prime rate



Note that the PBOC switched from the loan benchmark rate system to the loan prime rate (LPR) system in Aug 2019



Insurance | Hong Kong Insurance - Life | January 9, 2024

#### **DISCLAIMER**

The content of this report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by and belongs to CGS-CIMB. Reports relating to a specific geographical area are produced and distributed by the corresponding CGS-CIMB entity as listed in the table below.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the "Restrictions on Distributions" set out below). Any failure to comply with these limitations may constitute a violation of law. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CGS-CIMB.

The information contained in this research report is prepared from data believed to be correct and reliable at the time of issue of this report. CGS-CIMB may or may not issue regular reports on the subject matter of this report at any frequency and may cease to do so or change the periodicity of reports at any time. CGS-CIMB has no obligation to update this report in the event of a material change to the information contained in this report. CGS-CIMB does not accept any obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant, (ii) ensure that the content of this report constitutes all the information a prospective investor may require, (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, CGS-CIMB, its affiliates and related persons including CGS International Holdings Limited ("CGSIHL") and its related corporations (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. In particular, CGS-CIMB disclaims all responsibility and liability for the views and opinions set out in this report.

Unless otherwise specified, this report is based upon sources which CGS-CIMB considers to be reasonable. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research.

Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of CGS-CIMB or any of its affiliates (including CGSIHL and its related corporations) to any person to buy or sell any investments.

CGS-CIMB, its affiliates and related corporations (including CGSIHL and its related corporations) and/or their respective directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, CGS-CIMB, its affiliates and their respective related corporations (including CGSIHL and its related corporations) do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

CGS-CIMB or its affiliates (including CGSIHL and its related corporations) may enter into an agreement with the company(ies) covered in this report relating to the production of research reports. CGS-CIMB may disclose the contents of this report to the company(ies) covered by it and may have amended the contents of this report following such disclosure.

The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report. The analyst(s) who prepared this research report is prohibited from receiving any compensation, incentive or bonus based on specific investment banking transactions or for providing a specific recommendation for, or view of, a particular company. Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations and the research personnel involved in the preparation of this report may also participate in the solicitation of the businesses as described above. In reviewing this research report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request.

Reports relating to a specific geographical area are produced by the corresponding CGS-CIMB entity as listed in the table below. The term "CGS-CIMB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case except as otherwise stated herein, CGS-CIMB Securities International Pte. Ltd. and its affiliates, subsidiaries and related corporations.



Insurance | Hong Kong

Insurance - Life | January 9, 2024

Country	CGS-CIMB Entity	Regulated by
Hong Kong	CGS-CIMB Securities (Hong Kong) Limited	Securities and Futures Commission Hong Kong
Indonesia	PT CGS-CIMB Sekuritas Indonesia	Financial Services Authority of Indonesia
Malaysia	CGS-CIMB Securities Sdn. Bhd.	Securities Commission Malaysia
Singapore	CGS-CIMB Securities (Singapore) Pte. Ltd.	Monetary Authority of Singapore
South Korea	CGS-CIMB Securities (Hong Kong) Limited, Korea Branch	Financial Services Commission and Financial Supervisory Service
Thailand	CGS-CIMB Securities (Thailand) Co. Ltd.	Securities and Exchange Commission Thailand

## **Other Significant Financial Interests:**

(i) As of January 8, 2024 CGS-CIMB has a proprietary position in the securities (which may include but not be limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a) ·

(ii) Analyst Disclosure: As of January 9, 2024, the analyst(s) who prepared this report, and the associate(s), has / have an interest in the securities (which may include but not be limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a) -

This report does not purport to contain all the information that a prospective investor may require. Neither CGS-CIMB nor any of its affiliates (including CGSIHL and its related corporations) make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. Neither CGS-CIMB nor any of its affiliates nor their related persons (including CGSIHL and its related corporations) shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CGS-CIMB's clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments or any derivative instrument, or any rights pertaining thereto. Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this research report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

# Restrictions on Distributions

Australia: Despite anything in this report to the contrary, this research is provided in Australia by CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited. This research is only available in Australia to persons who are "wholesale clients" (within the meaning of the Corporations Act 2001 (Cth) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. You represent and warrant that if you are in Australia, you are a "wholesale client". This research is of a general nature only and has been prepared without taking into account the objectives, financial situation or needs of the individual recipient. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited do not hold, and are not required to hold an Australian financial services license. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited rely on "passporting" exemptions for entities appropriately licensed by the Monetary Authority of Singapore (under ASIC Class Order 03/1102) and the Securities and Futures Commission in Hong Kong (under ASIC Class Order 03/1103)

**Canada:** This research report has not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 – Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organization of Canada. For any research report distributed by CIBC, further disclosures related to CIBC conflicts of interest can be found at https://researchcentral.cibcwm.com.

China: For the purpose of this report, the People's Republic of China ("PRC") does not include the Hong Kong Special Administrative Region, the Macau Special Administrative Region or Taiwan. The distributor of this report has not been approved or licensed by the China Securities Regulatory Commission or any other relevant regulatory authority or governmental agency in the PRC. This report contains only marketing information. The distribution of this report is not an offer to buy or sell to any person within or outside PRC or a solicitation to any person within or outside of PRC to buy or sell any instruments described herein. This report is being issued outside the PRC to a limited number of institutional investors and may not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose.

**France:** Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument.

**Germany:** This report is only directed at persons who are professional investors as defined in sec 31a(2) of the German Securities Trading Act (WpHG). This publication constitutes research of a non-binding nature on the market situation and the investment instruments cited here at the time of the publication of the information.

The current prices/yields in this issue are based upon closing prices from Bloomberg as of the day preceding publication. Please note that neither the German Federal Financial Supervisory Agency (BaFin), nor any other supervisory authority exercises any control over the content of this report.

Hong Kong: This report is issued and distributed in Hong Kong by CGS-CIMB Securities (Hong Kong) Limited ("CHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities) and Type 4 (advising on securities) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CGS-CIMB Securities (Hong Kong) Limited. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its opinion or the information in this research report.



Insurance | Hong Kong Insurance - Life | January 9, 2024

This publication is strictly confidential and is for private circulation only to clients of CHK.

CHK does not make a market on other securities mentioned in the report.

None of the analyst(s) or the associates serve as an officer of the listed corporation mentioned in this report.

CIMB does not have an officer serving in any of the listed corporation mentioned in this report

CIMB does not receive any compensation or other benefits from any of the listed corporation mentioned, relating to the production of research reports.

Indonesia: This report is issued and distributed by PT CGS-CIMB Sekuritas Indonesia ("CGS-CIMB Indonesia"). The views and opinions in this research report are our own as of the date hereof and are subject to change. CGS-CIMB Indonesia has no obligation to update its opinion or the information in this research report. This report is for private circulation only to clients of CGS-CIMB Indonesia. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable Indonesian capital market laws and regulations.

This research report is not an offer of securities in Indonesia. The securities referred to in this research report have not been registered with the Financial Services Authority (Otoritas Jasa Keuangan) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market law and regulations.

**Ireland:** CGS-CIMB is not an investment firm authorised in the Republic of Ireland and no part of this document should be construed as CGS-CIMB acting as, or otherwise claiming or representing to be, an investment firm authorised in the Republic of Ireland.

Malaysia: This report is distributed in Malaysia by CGS-CIMB Securities Sdn. Bhd. ("CGS-CIMB Malaysia") solely for the benefit of and for the exclusive use of our clients. Recipients of this report are to contact CGS-CIMB Malaysia, at Level 29, Menara Aras Raya, No. 11, Jalan Raja Laut, 50350 Kuala Lumpur, Malaysia, in respect of any matters arising from or in connection with this report. CGS-CIMB Malaysia has no obligation to update, revise or reaffirm its opinion or the information in this research report after the date of this report.

New Zealand: In New Zealand, this report is for distribution only to persons who are wholesale clients pursuant to section 5C of the Financial Advisers Act 2008

**Singapore:** This report is issued and distributed by CGS-CIMB Securities (Singapore) Pte Ltd ("CGS-CIMB Singapore"). CGS-CIMB Singapore is a capital markets services licensee under the Securities and Futures Act 2001. Accordingly, it is exempted from the requirement to hold a financial adviser's licence under the Financial Advisers Act, 2001 ("FAA") for advising on investment products, by issuing or promulgating research analyses or research reports, whether in electronic, print or other form. CGS-CIMB Singapore is subject to the applicable rules under the FAA unless it is able to avail itself to any prescribed exemptions.

Recipients of this report are to contact CGS-CIMB Singapore, 10 Marina Boulevard, Marina Bay Financial Centre Tower 2, #09-01, Singapore 018983 in respect of any matters arising from, or in connection with this report. CGS-CIMB Singapore has no obligation to update its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only. If you have not been sent this report by CGS-CIMB Singapore directly, you may not rely, use or disclose to anyone else this report or its contents.

If the recipient of this research report is not an accredited investor, expert investor or institutional investor, CGS-CIMB Singapore accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. If the recipient is an accredited investor, expert investor or institutional investor, the recipient is deemed to acknowledge that CGS-CIMB Singapore is exempt from certain requirements under the FAA and its attendant regulations, and as such, is exempt from complying with the following:

- (a) Section 34 of the FAA (obligation to disclose product information);
- (b) Section 36 (duty not to make recommendation with respect to any investment product without having a reasonable basis where you may be reasonably expected to rely on the recommendation) of the FAA;
- (c) MAS Notice on Information to Clients and Product Information Disclosure [Notice No. FAA-N03];
- (d) MAS Notice on Recommendation on Investment Products [Notice No. FAA-N16];
- (e) Section 45 (obligation on disclosure of interest in specified products), and
- (f) any other laws, regulations, notices, directive, guidelines, circulars and practice notes which are relates to the above, to the extent permitted by applicable laws, as may be amended from time to time, and any other laws, regulations, notices, directive, guidelines, circulars, and practice notes as we may notify you from time to time. In addition, the recipient who is an accredited investor, expert investor or institutional investor acknowledges that as CGS-CIMB Singapore is exempt from Section 36 of the FAA, the recipient will also not be able to file a civil claim against CGS-CIMB Singapore for any loss or damage arising from the recipient's reliance on any recommendation made by CGS-CIMB Singapore which would otherwise be a right that is available to the recipient under Section 36 of the FAA.

CGS-CIMB Singapore, its affiliates and related corporations, their directors, associates, connected parties and/or employees may own or have positions in specified products of the company(ies) covered in this research report or any specified products related thereto and may from time to time add to or dispose of, or may be materially interested in, any such specified products. Further, CGS-CIMB Singapore, its affiliates and its related corporations do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in specified products of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

CGS-CIMB Singapore does not make a market on other specified products mentioned in the report.

**South Korea:** This report is issued and distributed in South Korea by CGS-CIMB Securities (Hong Kong) Limited, Korea Branch ("CGS-CIMB Korea") which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea. In South Korea, this report is for distribution only to professional investors under Article 9(5) of the Financial Investment Services and Capital Market Act of Korea ("FSCMA").

**Spain:** This document is a research report and it is addressed to institutional investors only. The research report is of a general nature and not personalised and does not constitute investment advice so, as the case may be, the recipient must seek proper advice before adopting any investment



Insurance | Hong Kong

Insurance - Life | January 9, 2024

decision. This document does not constitute a public offering of securities.

CGS-CIMB is not registered with the Spanish Comision Nacional del Mercado de Valores to provide investment services.

**Sweden:** This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden.

**Switzerland:** This report has not been prepared in accordance with the recognized self-regulatory minimal standards for research reports of banks issued by the Swiss Bankers' Association (Directives on the Independence of Financial Research).

**Thailand:** This report is issued and distributed by CGS-CIMB Securities (Thailand) Co. Ltd. ("CGS-CIMB Thailand") based upon sources believed to be reliable (but their accuracy, completeness or correctness is not guaranteed). The statements or expressions of opinion herein were arrived at after due and careful consideration for use as information for investment. Such opinions are subject to change without notice and CGS-CIMB Thailand has no obligation to update its opinion or the information in this research report.

# Corporate Governance Report (CGR): (Thai CGR and Anti-Corruption of Thai Listed Companies - Click here)

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. CGS-CIMB Thailand does not confirm nor certify the accuracy of such survey result.

Score Range:	90 - 100	80 – 89	70 - 79	Below 70	No Survey Result
Description:	Excellent	Very Good	Good	N/A	N/A

**United Arab Emirates:** The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates.

**United Kingdom and European Economic Area (EEA):** In the United Kingdom and European Economic Area, this material is also being distributed by CGS-CIMB Securities (UK) Limited ("CGS-CIMB UK"). CGS-CIMB UK is authorized and regulated by the Financial Conduct Authority and its registered office is at 53 New Broad Street, London EC2M 1JJ. The material distributed by CGS-CIMB UK has been prepared in accordance with CGS-CIMB's policies for managing conflicts of interest arising as a result of publication and distribution of this material. This material is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of CGS-CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (c) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order; (d) are outside the United Kingdom subject to relevant regulation in each jurisdiction, material(all such persons together being referred to as "relevant persons"). This material is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

This material is categorised as non-independent for the purposes of CGS-CIMB UK and therefore does not provide an impartial or objective assessment of the subject matter and does not constitute independent research. Consequently, this material has not been prepared in accordance with legal requirements designed to promote the independence of research and will not be subject to any prohibition on dealing ahead of the dissemination of research. Therefore, this material is considered a marketing communication.

United States: This research report is distributed in the United States of America by CGS-CIMB Securities (USA) Inc, a U.S. registered broker-dealer and an affiliate of CGS-CIMB Securities Sdn. Bhd., CGS-CIMB Securities (Singapore) Pte Ltd, PT CGS-CIMB Sekuritas Indonesia, CGS-CIMB Securities (Thailand) Co. Ltd and CGS-CIMB Securities (Hong Kong) Limited and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. CGS-CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc.

CGS-CIMB Securities (USA) Inc. does not make a market on other securities mentioned in the report.

CGS-CIMB Securities (USA) Inc. has not managed or co-managed a public offering of any of the securities mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not received compensation for investment banking services from any of the company mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. neither expects to receive nor intends to seek compensation for investment banking services from any of the company mentioned within the next 3 months.

United States Third-Party Disclaimer: If this report is distributed in the United States of America by Raymond James & Associates, Inc ("RJA"), this report is third-party research prepared for and distributed in the United States of America by RJA pursuant to an arrangement between RJA and CGS-CIMB Securities International Pte. Ltd. ("CGS-CIMB"). CGS-CIMB is not an affiliate of RJA. This report is distributed solely to persons who qualify as "U.S. Institutional Investors" or as "Major U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934, as



Insurance | Hong Kong

Insurance - Life | January 9, 2024

amended. This communication is only for U.S. Institutional Investors or Major U.S. Institutional Investor whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major U.S. Institutional Investor must not rely on this communication. The delivery of this report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. If you are receiving this report in the U.S from RJA, a FINRA/SIPC member, it takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc. or RJA. <a href="https://raymondjames.com/InternationalEquityDisclosures">https://raymondjames.com/InternationalEquityDisclosures</a>

**Other jurisdictions:** In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Distribution of stock ratings and investment banking clients for quarter ended on 30 September 2023			
634 companies under coverage for quarter en	ded on 30 September 2023		
	Rating Distribution (%)	Investment Banking clients (%)	
Add	66.7%	0.9%	
Hold	23.7%	0.0%	
Reduce	9.6%	0.2%	

Recommendation	Framework			
Stock Ratings	Definition:			
Add	The stock's total return is expected to exceed 10% over the next 12 months.			
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.			
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.			
	eturn of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net stock. Stock price targets have an investment horizon of 12 months.			
Sector Ratings	Definition:			
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.			
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.			
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.			
Country Ratings	Definition:			
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.			
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.			
	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.			

#03c